Endocrine Abstracts

Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.Methods: Eighteen patients (11 males; age 56.7±2.5) with proven progressive disease...

Objective: The ITT is the gold-standard for assessment of GH and ACTH reserve but has certain contraindications. GH and cortisol responses of <3 ng/ml and <500 nmol/l, respectively, have been defined as evidence of severe deficiency. The GST like the ITT stimulates both the ACTH and GH secretion and is suggested to be a good alternative in terms of efficiacy. However, there are limited prospective data with modern assays on sensitivity and specificity for the GST in co...

Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with only limited effective systemic treatment options. The identification of actionable genetic lesions and its exploitation has expanded therapeutic approaches and especially for the subset of BRAFV600E mutated ATC (11-25%) combined BRAF- and MEK-inhibition indicated meaningful activity. Still, further effective therapeutic options are required for patients without identifiable driver mutations. The role ...

Therapeutic strategy for the management of radioiodine-refractory differentiated thyroid cancer (rrDTC) and advanced medullary thyroid cancer (MTC) had changed with the introduction of the multityrosine-kinase-inhibitors (MKI) sorafenib&lenvatinib and vandetanib&cabozantinib respectively. Only recently, the market approval of pralsetinib (FDA) and selpercatinib (FDA and EMA) as first highly selective RET(rearranged during transfection)- inhibitors have expande...

Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...

Objective: While Germany was considered to be an iodine deficient area grade I to II in 1993, iodine supply has increased. With higher iodine uptake, prevalence of autoimmune thyroiditis may increase. Poor data exist on iodine supply and the occurrence of thyroid dysfunction in middle-aged adults in the western part of Germany. The aim of our study was to analyze iodine status, prevalence of TPO-antibodies (TPOab), TSH and fT4 levels in a large population-based sample in the w...